An oral Covid-19 treatment developed by Atea Pharmaceuticals failed in a midstage trial, the company said Tuesday, sending the company’s stock tumbling
Experimental treatment doesn’t cut viral load in nonhospitalized patients with mild to moderate symptoms; stock plunges 61%
Doctors are increasingly turning to monoclonal antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why COVID-19 booster shots weren't tweaked to better match Delta variantMore COVID-19 booster shots may be on the way — but when it’s your turn, you’ll get an extra dose of the original vaccine formulation, not one updated to better match the extra-contagious Delta variant.
Read more »
U.S. administers 408.3 mln doses of COVID-19 vaccines - CDCThe United States has administered 408,265,959 doses of COVID-19 vaccines as of Sunday morning, the Centers for Disease Control and Prevention said.
Read more »
Covid-19 booster shots: What you need to knowThe Food and Drug Administration is poised to dramatically expand the use of Covid-19 booster shots as soon as this week, after weeks of public debate over who needs the shots — and when
Read more »
EU says exports of COVID-19 vaccines now top 1 billion markThe European Union says it now has exported over 1 billion doses of COVID-19 vaccines to the rest of the world.
Read more »